25537-64-8Relevant articles and documents
Amide compounds and uses thereof
-
Page/Page column 62, (2021/10/11)
Provided herein are novel amide compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the definition of each symbol is as described in the description.
LPA RECEPTOR ANTAGONISTS AND USES THEREOF
-
, (2021/12/17)
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM
-
Page/Page column 58-59, (2021/11/20)
The invention provides novel compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
-
Paragraph 0286-0287, (2021/05/21)
The present disclosure relates generally to compounds of Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
LPA RECEPTOR ANTAGONISTS AND USES THEREOF
-
Paragraph 0214, (2021/12/31)
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
Synthesis of a Water-Soluble, Soft N-Donor BTzBP Ligand Containing only CHON
Albright, Savannah G.,Ali, Bakr,Chapman, Hayley A.,Cheng, Yijie,Cusic, Rachel M.,Friese, Seth J.,Hartlove, Nathan B.,Labb, Samantha A.,Marr, Alissa N.,Masteran, Conner J.,Timmons, Miranda
supporting information, p. 1384 - 1388 (2020/08/03)
A hydrophilic ligand that contains only C, H, O, and N substituents and uses a 6,6′-bis(1 H -1,2,3-triazol-4-yl)-2,2′-bipyridine (BTzBP) structural core has been synthesized. The effect of adding water-soluble groups onto extractant ligands has been extensively studied to facilitate the efficient partitioning of 4f and transuranic 5f elements for the treatment of spent nuclear fuel. Soft, N-donor ligands exhibit greater binding affinities for the trivalent actinides over the trivalent lanthanides, making BTzBP ligands an ideal candidate in the search for extractants to be used on an industrial scale. To date, hydrophobic BTzBPs have been shown to exhibit physical and chemical properties that might be conducive to nuclear waste processing conditions. However, hydrophilic BTzBPs have yet to be reported. Herein, we show the synthesis of a hydrophilic BTzBP ligand featuring cationic water solubilizing groups attached to the bipyridal rings.
PROCESS FOR PREPARING CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACID COMPOUNDS
-
Page/Page column 56-57, (2020/10/27)
Improved methods and intermediates thereof for preparing carbamoyloxy methyl triazole cyclohexyl acid compounds are described. These compounds are useful as LPA antagonists. Formula (I).
DIHYDROPYRROLOPYRAZINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER
-
Page/Page column 67-68, (2017/05/28)
The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 has any of the meanings hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and t
Preparation method of 1-subtituted-1H-1,2,3-triazole-4-carboxylic acid
-
Paragraph 0041; 0042; 0043, (2016/10/09)
The invention provides a preparation method of 1-subtituted-1H-1,2,3-triazole-4-carboxylic acid. The preparation method includes the following steps: 1-substituted-4,5-dibromo-1H-1,2,3-triazole is added to an isopropylmagnesium chloride, such that 1-substituted-4-bromo-1H-1,2,3-triazole is obtained through a reaction; an isopropylmagnesium chloride-lithium chloride complex is added directly, such that a mixture of 1-substituted-1H-1,2,3-triazole-4-carboxylic acid and 1-substituted-4-bromo-1H-1,2,3-triazole-5-carboxylic acid is obtained; a base and iodomethane are added to the mixture, such that methyl 1-substituted-4-bromo-1H-1,2,3-triazole-5-carboxylare is obtained through a reaction; the aqueous layer is adjusted with hydrochloric acid until a pH value is 1-5; extraction is carried out with an organic solvent, and drying and concentration crystallization are carried out, such that 1-substituted-1H-1,2,3-triazole-4-carboxylic acid is obtained. The method is suitable for industrial production, and has a great application value.
COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS
-
Page/Page column 82-83, (2012/10/18)
The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).
